These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 30902750)

  • 1. Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
    Tronieri JS; Wadden TA; Walsh OA; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Chao AM
    Metabolism; 2019 Jul; 96():83-91. PubMed ID: 30902750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
    Winslow DH; Bowden CH; DiDonato KP; McCullough PA
    Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial.
    Tronieri JS; Wadden TA; Walsh O; Berkowitz RI; Alamuddin N; Gruber K; Leonard S; Bakizada ZM; Chao AM
    Int J Obes (Lond); 2020 Feb; 44(2):353-361. PubMed ID: 30926955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy for obesity.
    Lee PC; Dixon J
    Aust Fam Physician; 2017; 46(7):472-477. PubMed ID: 28697290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
    Dalai SS; Adler S; Najarian T; Safer DL
    Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
    Wadden TA; Tronieri JS; Sugimoto D; Lund MT; Auerbach P; Jensen C; Rubino D
    Obesity (Silver Spring); 2020 Mar; 28(3):529-536. PubMed ID: 32090517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
    Wadden TA; Hollander P; Klein S; Niswender K; Woo V; Hale PM; Aronne L;
    Int J Obes (Lond); 2013 Nov; 37(11):1443-51. PubMed ID: 23812094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults.
    Lean ME; Carraro R; Finer N; Hartvig H; Lindegaard ML; Rössner S; Van Gaal L; Astrup A;
    Int J Obes (Lond); 2014 May; 38(5):689-97. PubMed ID: 23942319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phentermine: an appetite-suppressant amphetamine classified as a narcotic in France. Is a combination with topiramate on the horizon?
    Prescrire Int; 2012 Sep; 21(130):209. PubMed ID: 23016252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
    Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
    Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
    Lundgren JR; Janus C; Jensen SBK; Juhl CR; Olsen LM; Christensen RM; Svane MS; Bandholm T; Bojsen-Møller KN; Blond MB; Jensen JB; Stallknecht BM; Holst JJ; Madsbad S; Torekov SS
    N Engl J Med; 2021 May; 384(18):1719-1730. PubMed ID: 33951361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Greater hunger and less restraint predict weight loss success with phentermine treatment.
    Thomas EA; Mcnair B; Bechtell JL; Ferland A; Cornier MA; Eckel RH
    Obesity (Silver Spring); 2016 Jan; 24(1):37-43. PubMed ID: 26584649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
    Bays H
    Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
    Astrup A; Carraro R; Finer N; Harper A; Kunesova M; Lean ME; Niskanen L; Rasmussen MF; Rissanen A; Rössner S; Savolainen MJ; Van Gaal L;
    Int J Obes (Lond); 2012 Jun; 36(6):843-54. PubMed ID: 21844879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.